PharmaShots | Incisive News in 3 Shots

Subscribe Now

Novartis

Novartis Presents P-III Trial (APPOINT-PNH) Results of Iptacopan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria at EBMT 2023

Novartis Presents P-III Trial (APPOINT-PNH) Results of Iptacopan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria at EBMT...

April 27, 2023

Novartis Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Cosentyx (secukinumab) for Hidradenitis Suppurativa

Novartis Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Cosentyx (secukinumab) for Hidradenitis Supp...

April 26, 2023

Novartis to Present Five-Year (ALITHIOS) Open-Label Extension Study Results of Kesimpta (ofatumumab) for Relapsing Multiple Sclerosis at AAN 2023

Novartis to Present Five-Year (ALITHIOS) Open-Label Extension Study Results of Kesimpta (ofatumumab) for Relapsing Multiple Sclero...

April 20, 2023

Insights+: The US FDA New Drug Approvals in March 2023

Insights+: The US FDA New Drug Approvals in March 2023

April 19, 2023

PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

April 3, 2023

Novartis Receives EMA’s CHMP Positive Opinion of Entresto (sacubitril/valsartan) for Heart Failure in Pediatric Patients

Novartis Receives EMA’s CHMP Positive Opinion of Entresto (sacubitril/valsartan) for Heart Failure in Pediatric Patients

March 31, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us